Ligand beats, raises 2026 EPS guidance

 

Ligand Pharmaceuticals beats Q3 2026 estimates with non-GAAP EPS $2.67 and revenue $78.7M, raises 2026 EPS guidance

• Q3 non-GAAP EPS $2.67, down 14% YoY, while revenue declined 32% YoY to $78.7M
• Q3 royalty revenue rose 51% to $70.3M, partially offsetting other declines
• Raises full-year 2026 adjusted EPS guidance to $9.50–$9.75 from $9.00–$9.50
• Reaffirms full-year 2026 revenue guidance

https://finviz.com/stock?t=LGND&ty=c&ta=1&p=d